

(LR 019)

NOVEMBER 2020
(AUGUST 2020 SESSION)

Sub. Code: 1303

D.M. – MEDICAL ONCOLOGY

**Paper III – MEDICAL ONCOLOGY INCLUDING THERAPY,
EPIDEMIOLOGY AND REHABILITATION**

Q.P. Code: 161303

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on:

(2 x 15 = 30)

1. Discuss the impact of COVID-19 on cancer management and patient outcome.
2. Discuss the epidemiology, clinical features, genetics, pathology, staging and treatment of cholangiocarcinoma.

II. Write notes on:

(10 x 7 = 70)

1. Informed consent.
2. Management of adult Philadelphia chromosome positive Acute Lymphoblastic Leukemia.
3. Chemotherapy in Ewings sarcoma.
4. Medical management of fibromatosis.
5. Define skeletal related adverse events. What is the role of bisphosphonates and denosumab in preventing skeletal related adverse events in patients with metastatic cancer?
6. WHO Global Initiative for Childhood Cancer 2018.
7. Assessment and management of cancer fatigue.
8. Neoadjuvant anti-Her2 treatment in breast cancer.
9. Cancer survivorship and late effects of treatment of pediatric cancer survivor
10. Classification of severity of chemotherapy induced vomiting and guidelines for prophylaxis for prevention of chemotherapy induced nausea and vomiting.
